Nimodipino Stadafarma (Nimodipine)

Nimodipine selectively blocks L‑type calcium channels on the smooth muscle of cerebral arteries. This blockade reduces calcium entry into the cells, causing the vessels to relax and dilate. The resulting vasodilation improves cerebral perfusion and lessens the likelihood of vasospasm after a hemorrhagic event.

The appropriate dose of Nimodipino Stadafarma is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. Dosage regimens are individualized and should follow the prescribing information provided by the healthcare professional.

Safety data for nimodipine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers must evaluate the risk‑benefit profile before prescribing to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimodipine is the only calcium‑channel blocker specifically approved for preventing cerebral vasospasm after subarachnoid hemorrhage. Other agents, such as clazosentan or endothelin‑receptor antagonists, target different pathways and have distinct safety profiles. Nimodipine’s oral route and well‑characterised pharmacology make it a first‑line option in many guidelines.

Store Nimodipino Stadafarma at ambient temperature below 25 °C. Keep the tablets in their original packaging, protect them from moisture, heat and direct sunlight. Do not refrigerate or freeze the product, as temperature extremes can affect tablet integrity.

Nimodipino Stadafarma is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional. Administration timing (e.g., with or without food) follows the prescriber’s instructions.

The most serious risks include severe hypotension, bradycardia, and rare but potentially life‑threatening allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for sudden drops in blood pressure, slow heart rate, or any signs of hypersensitivity, and medical attention should be sought immediately if they occur.

Nimodipino Stadafarma should be avoided in individuals with known hypersensitivity to nimodipine or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, uncontrolled hypotension, or those taking contraindicated strong CYP3A4 inhibitors. The prescriber decides suitability on a case‑by‑case basis.